Clinical Trial Update: COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19) [Phase 3]

View source ↗

Summary

Phase 3 trial COVID-OUT evaluated early outpatient treatment of SARS-CoV-2 infection with nitazoxanide, ivermectin, and fluvoxamine; results were posted in July…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syndrome

Drugs mentioned

• Fluvoxamine (Luvox) (Fluvoxamine)
• IVERMECTIN (Ivermectin)
• Nitazoxanide (Alinia) (nitazoxanide)

Snippet

Sponsor: University of Minnesota | Conditions: Covid19, SARS-CoV Infection | Phase 3 | Status: COMPLETED | Results posted: 2023-07-13